First APDS Therapy Advances
FDA Accepts Pharming's Joenja Application for First APDS Therapy in Young Children
Anonymous
Pharming announced the FDA has accepted its resubmitted supplemental application for Joenja (leniolisib) to expand treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) to children ages 4 to 11, following a prior Complete Response Letter that stemmed from questions about analytical methods used in production batch testing rather than the underlying clinical results. The agency’s review is now underway, with a late-2026 Prescription Drug User Fee Act target date, after Pharming met with the FDA in late March 2026 and provided additional manufacturing analytical data. If approved, Joenja would be the first FDA-cleared APDS therapy for U.S. children in this age range. The resubmission targets 40 mg and 50 mg twice-daily dosing for patients weighing at least 27 kilograms, while Pharming plans a separate sNDA later in 2026 for lower-weight children. The submission is supported by positive Phase III open-label, single-arm data showing improvements over about 12 weeks in key APDS disease markers, including reduced lymphadenopathy and increased naïve B cells, with no drug-related serious safety events reported. The staggered submissions mean access would likely expand in stages, with the lower-weight cohort reviewed after the higher-weight decision.
Key Points
1
FDA assigned a specific PDUFA target action date of October 24, 2026 for its review of the resubmitted sNDA.
2
Pharming’s resubmission followed a Complete Response Letter on January 30, 2026 and a Type A meeting with FDA on March 26, 2026, after which the company provided additional analytical batch-testing information.
3
The clinical rationale highlighted by one report emphasizes APDS’s serious progression: the article notes a reported median seven-year diagnostic delay and warns that delayed treatment can lead to permanent lung damage and higher lymphoma risk—motivating treatment at age 4 to interrupt pathology earlier.
4
Beyond the absence of drug-related serious safety events, one report specifies that all treatment-emergent adverse events were graded mild to moderate and that there were zero drug-related serious adverse events during the 12-week open-label period.
5
There is a reported discrepancy on the PDUFA target date: GeneOnline stated September 28, 2026 as the target action date, while other outlets cited October 24, 2026.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
22
Reach
32
A
AnonymousAuthor
